NicOx.... in attesa di.....


VOLUNTARY ANNOUNCEMENT PRIMARY CLINICAL ENDPOINT ACHIEVED IN THE PHASE III CLINICAL TRIAL OF OT-1001 This announcement is made by Ocumension Therapeutics (the “Company”, together with its subsidiaries, the “Group”) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group. The board (the “Board”) of directors of the Company is pleased to announce that the phase III clinical trial of OT-1001 (ZERVIATE), a potent and highly selective histamine-1 receptor antagonist with anti-allergic properties, has achieved its primary clinical endpoint and received positive results. OT-1001 (ZERVIATE) was developed by Nicox Ophthalmics, Inc. (“Nicox”). OT-1001 is the first and only eye drop formulation of the antihistamine cetirizine, the active ingredient in ZYRTEC®, and is currently commercialized in the United States for ocular itching associated with allergic conjunctivitis. Studies have shown that OT-1001 is a safe and effective antihistamine therapeutic agent. OT-1001 has a rapid onset of action, and the effect is able to last for at least 8 hours after administration. OT-1001 covers a wide range of patients. In addition to treating adult patients, the safety and effectiveness of OT-1001 has been established in pediatric patients two years of age and older, therefore meeting the current clinical needs of treating pediatric patients with allergic conjunctivitis. The Group obtained an exclusive license from Nicox to develop, make, have made, import, export, use, distribute, market, promote, offer for sale and sell (or otherwise commercialize) OT-1001 (ZERVIATE) in the Greater China region in March 2019, and extended the exclusive rights to 11 countries in Southeast Asia in March 2020. In December 2020, the first patient has been successfully enrolled and dosed in the phase III clinical trial of OT-1001 in China. The phase III clinical trial of OT-1001 was designed as a randomized, observer-masked, positive control, multi-center parallel clinical trial to evaluate the safety and efficacy of the cetirizine hydrochloride ophthalmic solution of 0.24% concentration in comparison with emedastine difumarate ophthalmic solution of 0.05% concentration for Chinese patients with allergic conjunctivitis. A total of 296 patients were randomized across multiple clinical sites in China. OT-1001 was found to be non-inferior to emedastine difumarate in the primary efficacy endpoint of change from baseline in the itching score in the 24 hours prior to the Day 14 visit. OT-1001 was safe and well-tolerated with no difference in the proportion of patients with adverse events compared to emedastine difumarate. The successful completion of this clinical trial is an important step towards commercialization of OT-1001. 2 Cautionary Statement: The Company cannot guarantee that it will ultimately commercialize OT-1001 (ZERVIATE) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.
 
malgré ce newsflow tres tres interessant et je pese mes mots , elle n'attire décidemment pas les investisseurs !! la situation n'aide clairement pas... mais tout de meme

cette valeur j'en suis certain merite bien mieux :(
 
sensorion n'a diffusé aucune news , ah si une seule debut janvier indiquant un echec de phase 2b pour sens 401 avec un espoir sur un sous groupe lors des resultats complementaires communiqués en mars...

elle prend 60% cette semaine, et valorise 73M 77m soit quasi 10M de moins que Nicox...

la bas personne ne vend.. un capital avec des fonds identifies a plus de 50% sont soffinova et invus

ici ca continue a balancer malgré les news positives des ATP de 10 ou 15k sur les plus bas historiques à 40 cents d'une AK que beaucoup consideraient comme un pseudo vol ...

il faut vraiment avoir la foi et les nerfs bien accrochés...
 
Ultima modifica:
les brevets NCX470 NCX4251 ZERVIATE VYZULTA qui sont géres parfaitement par la team des brevets !

une reunion positive NCX4251 !

Un vyzulta qui progresse bien au niveau des prescriptions et dont B+L etend l'espace de vente mondial

Zerviate chine OK

une bonne interview du ceo qui affiche sa confiance pleine et lucide pour l'avenir !!

et la cerise sur le gateau le napro qui devient medicament orphelin !!!


que veut le marche en plus ???
 
elfrancese ha scritto:
malgré ce newsflow tres tres interessant et je pese mes mots , elle n'attire décidemment pas les investisseurs !! la situation n'aide clairement pas... mais tout de meme

cette valeur j'en suis certain merite bien mieux :(
Clicca per allargare...
Credo che ti rendi conto che siamo sul baratro della terza e ultima guerra mondiale e quindi certe considerazioni non hanno senso.
Qui c'è da preoccuparsi di altro non vedi che i russi ogni giorno alzano il livello di tensione e nei loro comunicati ormai usano solo la parola guerra nucleare ?
Qui è chiaro che o gli lasciamo fare quello che vogliono o questi pazzi la guerra nucleare la scatenano,mi spiace dirlo ma non possiamo rischiare questo per l'Ucraina,non ci possiamo fare trascinare oltre quello che abbiamo fatto, questi prendono a pretesto qualsiasi cosa pur di scatenare una guerra,spero solo che Dio riservi il peggior posto nell'inferno a questo bastardo sanguinario.
 
Ultima modifica:
Capture d’écran 2022-03-02 173249.png
 
+0,24% soit 0,05 cent en plus

le marché est trop bon...
qui peut croire qu'il n'existe pas un contrôle en place sur le cours de nicox 5/5 jours ???
 
Ultima modifica:
You must log in or register to reply here.

Similar threads

DickSIM
Pharma e Biotech - Europa NicOx..aspettando non si sa cosa..senza il NET-ZOHAR!!
2 3 4
Risposte
35
Visite
5.625
DickSIM
DickSIM

Users who are viewing this thread

Total: 1 (members: 0, guests: 1)
Back
Alto